Allogene Therapeutics Inc represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company aims to revolutionize the field of cancer treatment by harnessing the potential of allogeneic cell therapies. By leveraging cutting-edge technologies and strategic partnerships, Allogene Therapeutics Inc strives to deliver transformative therapies to patients worldwide. With a focus on improving outcomes and addressing unmet medical needs, the company is committed to advancing breakthrough therapies for various types of cancer. Allogene Therapeutics Inc's dedication to scientific excellence and commitment to patients underscores its mission to bring novel cell therapies to market and improve the lives of those affected by cancer.

Allogene Therapeutics Inc primarily operates in the United States.

Allogene Therapeutics Inc has achieved significant milestones since its establishment. Notably, the company successfully completed its initial public offering in October 2018, raising a substantial amount of capital to support its research and development efforts. The following year, Allogene Therapeutics initiated its first clinical trial evaluating its proprietary allogeneic CAR-T therapy, ALLO-501, for the treatment of relapsed/refractory non-Hodgkin lymphoma. Moreover, in 2020, the company received the prestigious Breakthrough Therapy Designation from the U.S. FDA for ALLO-501, recognizing its potential to address unmet medical needs. These achievements highlight Allogene Therapeutics' commitment to advancing innovative cellular therapies to transform the lives of patients with cancer.

Allogene Therapeutics Inc. is a biotechnology company specializing in the development of innovative cell therapies for cancer treatment. Founded in 2018, the company has quickly gained recognition for its groundbreaking approach to utilizing allogeneic, or off-the-shelf, CAR T cell therapy. With a mission to revolutionize cancer treatment, Allogene Therapeutics has established strategic partnerships and collaborations to accelerate the development and commercialization of their therapies. They aim to provide potentially curative treatments for patients battling various types of cancer. Allogene Therapeutics Inc. is committed to advancing the field of cellular immunotherapy in its quest to improve patient outcomes and transform cancer care.

The main competitors of Allogene Therapeutics Inc in the market include companies like Novartis AG, Pfizer Inc, and Cellectis SA.

Allogene Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

Allogene Therapeutics Inc is a biotechnology company specializing in the development of allogeneic T cell therapies for cancer treatment. Their business model revolves around the advancement and commercialization of groundbreaking immunotherapies. By harnessing the power of genetically engineered T cells from healthy donors, Allogene aims to provide readily available and potentially more effective therapeutic options for patients. The company collaborates with academic institutions, pharmaceutical companies, and pioneers in the field to accelerate the development of innovative treatments. Allogene Therapeutics Inc's business model focuses on transforming cancer care through the utilization of allogeneic cell therapies, aiming to improve patient outcomes and contribute to the advancement of oncology research.

Allogene Therapeutics KGV ir -1,27.

Allogene Therapeutics KUV ir 6237,35.

AlleAktien kvalitātes vērtējums Allogene Therapeutics ir 2/10.

gaidāmā Allogene Therapeutics apgrozījums ir 65 667,60 USD.

gaidāmā Allogene Therapeutics peļņa ir -321,53 milj. USD.

Allogene Therapeutics Inc is an innovative biopharmaceutical company specializing in the development of allogeneic CAR-T therapies for the treatment of severe cancers. The company focuses on developing gene therapies that can specifically target and destroy cancer cells due to their high effectiveness and specific mode of action. The company has a unique business model that enables the development and commercialization of cancer treatments in innovative ways. By using allogeneic cells from other donors instead of autologous cells from the patient, Allogene Therapeutics can offer faster and more cost-effective treatments. The treatment can be completed within a few weeks. The company aims to develop and market a wide range of allogeneic therapies for various types of cancer. They are working on developing gene therapies that selectively activate the immune system to fight cancer cells. One of their key drug candidates is ALLO-501, an allogeneic CAR-T cell therapy program used in combination with lymphodepletion in patients with non-Hodgkin lymphoma (NHL). The company also has a wide range of product candidates, including ALLO-715, used for the treatment of patients with severe multiple myeloma, and ALLO-647, an immunosuppressive molecule designed to prevent potential immune reactions against allogeneic cell therapies. Through a partnership with Servier, Allogene Therapeutics has also gained a strategic position in Europe. This partnership aims to expand access to allogeneic CAR-T cells to meet the needs of patients with difficult-to-treat blood cancers. Recently, the company completed a funding round of over $700 million to further advance its clinical studies and development pipeline. The company plans to use these funds to conduct additional clinical trials and bring their product candidates to market. As a leading provider of allogeneic CAR-T therapies, Allogene Therapeutics is committed to revolutionizing cancer treatment. Their innovative business model and groundbreaking gene therapies have the potential to improve the lives of cancer patients worldwide and successfully fight against cancer.

Allogene Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Allogene Therapeutics vai uzņēmums nedod dividendes.

Allogene Therapeutics ISIN ir US0197701065.

Allogene Therapeutics WKN ir A2N6WN.

Allogene Therapeutics simbols ir ALLO.

Pēdējo 12 mēnešu laikā Allogene Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Allogene Therapeutics plāno maksāt dividendes 0 USD apmērā.

Allogene Therapeutics pašreizējā dividendu rentabilitāte ir .

Allogene Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Allogene Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Allogene Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Allogene Therapeutics apmērā 0 USD, kas tika izmaksāta 26.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.08.2024..

Pēdējās dividendes izmaksa notika 26.08.2024..

Gadā 2023, Allogene Therapeutics izmaksāja 0 USD dividendes.

Allogene Therapeutics dividendes tiek izmaksātas USD.